Clinical trials recruiting in Zhanjiang, China

Phase breakdown

Conditions recruiting in Zhanjiang, China

Recruiting trials in Zhanjiang, China

• A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
  NCT06103864 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
  NCT06119581 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
  NCT07174336 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
  NCT04928846 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
  NCT06023589 · Phase: Phase 3 · Ages: 5 Years to 11 Years · Sex: All (male and female)
• A Translational Study to Describe Clinical Characteristics, Biomarkers and to Identify Phenotypes and Endotypes Associated With Differential Outcomes in Chinese Population
  NCT06419413 · Phase: Not specified · Ages: 18 Years to 75 Years · Sex: All (male and female)
• ASPIrin in Reducing Events in Dialysis ( ASPIRED )
  NCT04381143 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female)
• Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer
  NCT06768931 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female
• D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure
  NCT06300177 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
  NCT07190209 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female)
• Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab
  NCT07363642 · Phase: Phase 3 · Ages: 12 Years to 80 Years · Sex: All (male and female)
• Radiotherapy After Prostatectomy for Node Positive Prostate Cancer
  NCT07477626 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male
• Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy
  NCT06862869 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy
  NCT07400523 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Female
• Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
  NCT06170788 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Transanal Versus Laparoscopic Total Mesorectal Excision for Rectal Cancer
  NCT02966483 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 75 Years · Sex: All (male and female)

Common questions

How many clinical trials are recruiting in Zhanjiang, China?

16 recruiting trials have at least one study site in Zhanjiang, China.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.